Currently out of the existing stock ratings of Madison El-Saadi, 30 are a BUY (96.77%), 1 are a HOLD (3.23%).

Madison El-Saadi

Work Performance Price Targets & Ratings Chart

Analyst Madison El-Saadi, currently employed at B. RILEY, carries an average stock price target met ratio of 27.08% that have a potential upside of 37.04% achieved within 94 days.

Madison El-Saadi’s has documented 59 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CAPR, Capricor Therapeutics at 14-Sep-2026.

Wall Street Analyst Madison El-Saadi

Analyst best performing recommendations are on WVE (WAVE LIFE SCIENCES LTD).
The best stock recommendation documented was for WVE (WAVE LIFE SCIENCES LTD) at 9/19/2024. The price target of $11 was fulfilled within 27 days with a profit of $5.06 (85.19%) receiving and performance score of 31.55.

Average potential price target upside

AXSM Axsome Therapeutics CAPR Capricor Therapeutics ETON Eton Pharmaceuticals VNDA Vanda Pharmaceuticals WVE Wave Life Sciences Ltd ARWR Arrowhead Pharmaceuticals CMPS Compass Pathways Plc OVID Ovid Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 25-Jan-2024

$295

$137.86 (87.73%)

$297

12 days ago
(08-Oct-2026)

18/22 (81.82%)

$124.92 (73.45%)

246

Buy Since 12-Dec-2023

$267

$109.86 (69.91%)

$176

21 days ago
(29-Sep-2026)

5/6 (83.33%)

$80.86 (43.44%)

319

Hold Since 30-Apr-2026

$247

$89.86 (57.18%)

$251

25 days ago
(25-Sep-2026)

8/10 (80%)

$51.91 (26.61%)

152

Buy Since 16-Jan-2024

$258

$100.86 (64.18%)

$258

1 months 2 days ago
(18-Sep-2026)

10/12 (83.33%)

$50.22 (24.17%)

171

Buy Since 07-Jun-2018

$290

$132.86 (84.55%)

$290

1 months 19 days ago
(31-Aug-2026)

45/52 (86.54%)

$91.48 (46.08%)

739

Show more analysts

Please expand the browser size to see the chart

Which stock is Madison El-Saadi most bullish on?

Potential upside of $142.86 has been obtained for AXSM (AXSOME THERAPEUTICS)

Which stock is Madison El-Saadi most reserved on?

Potential downside of $2.85 has been obtained for OVID (OVID THERAPEUTICS)

What Year was the first public recommendation made by Madison El-Saadi?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?